BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 36.55
+3.30 (9.92%)
Aug 15, 2025, 1:30 PM CST
BioGend Therapeutics Revenue
BioGend Therapeutics had revenue of 52.72M TWD in the quarter ending June 30, 2025, with 41.46% growth. This brings the company's revenue in the last twelve months to 195.02M, up 46.14% year-over-year. In the year 2024, BioGend Therapeutics had annual revenue of 167.65M with 52.53% growth.
Revenue (ttm)
195.02M
Revenue Growth
+46.14%
P/S Ratio
23.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.54B
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.83M |
| PharmaEssentia | 11.34B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Oneness Biotech | 112.57M |
| Polaris Group | 87.67M |
| Center Laboratories | 1.63B |
| Lumosa Therapeutics | 37.25M |